scholarly journals c-Met as a Target for Personalized Therapy

2015 ◽  
Vol Suppl. 1 ◽  
pp. 13-31 ◽  
Keyword(s):  
Personalized Therapy

CTCtrap – Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients

2014 ◽  
Vol 74 (S 01) ◽  
Author(s):  
H Neubauer ◽  
N Kasprowicz ◽  
B Rack ◽  
C Vizler ◽  
M Scholz ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Personalized Therapy

СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ АНГИООТЕКОВ В ПЕДИАТРИИ

2019 ◽  
Author(s):  
A.R. Denisova ◽  
A.N. Pampura
Keyword(s):  
Clinical Manifestations ◽  
Personalized Therapy ◽  
Diagnostics And Therapy ◽  
Selection Of

Ангиоотеки довольно часто встречаются в детском возрасте. Эффективность ведения детей с ангиоотеками определяется пониманием патогенеза заболевания и подбором персонифицированной терапии. В статье представлены сведения о классификации, клинических проявлениях, диагностике и терапии как брадикинин-, так и гистаминергических ангиоотеков.Angioedema often occurs in childhood. The effectiveness of the management of children with angioedema is determined by understanding the pathogenesis of the disease and the selection of personalized therapy. This article provides information on the classification, clinical manifestations, diagnostics and therapy of both bradykinin and histaminergic angioedema.

Molecular Foundations for Personalized Therapy in Prostate Cancer

2015 ◽  
Vol 16 (2) ◽  
pp. 103-114 ◽  
Author(s):  
Kurt W. Fisher ◽  
Rodolfo Montironi ◽  
Antonio Beltran ◽  
Holger Moch ◽  
Lisha Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Personalized Therapy

Precision Medicine in Patients with Differential Diabetic Phenotypes: Novel Opportunities from Network Medicine

2021 ◽  
Vol 18 ◽  
Author(s):  
Claudio Napoli ◽  
Giuditta Benincasa ◽  
Samer Ellahham
Keyword(s):  
Precision Medicine ◽  
Protein Interactions ◽  
Randomized Clinical Trials ◽  
Growth Factor Receptor ◽  
Cardiovascular Complications ◽  
Personalized Therapy ◽  
Network Medicine ◽  
Prediabetic State ◽  
Relevant Role ◽  
Approved Drugs

Introduction: Diabetes mellitus (DM) comprises differential clinical phenotypes ranging from rare monogenic to common polygenic forms, such as type 1 (T1DM), type 2 (T2DM), and gestational diabetes, which are associated with cardiovascular complications. Also, the high-risk prediabetic state is rising worldwide, suggesting the urgent need for early personalized strategies to prevent and treat a hyperglycemic state. Objective: We aim to discuss the advantages and challenges of Network Medicine approaches in clarifying disease-specific molecular pathways, which may open novel ways for repurposing approved drugs to reach diabetes precision medicine and personalized therapy. Conclusion: The interactome [or protein-protein interactions (PPIs)] is a useful tool to identify subtle molecular differences between precise diabetic phenotypes and predict putative novel drugs. Despite being previously unappreciated as T2DM determinants, the growth factor receptor-bound protein 14 (GRB14), calmodulin 2 (CALM2), and protein kinase C-alpha (PRKCA) might have a relevant role in disease pathogenesis. Besides, in silico platforms have suggested that diflunisal, nabumetone, niflumic acid, and valdecoxib may be suitable for the treatment of T1DM; phenoxybenzamine and idazoxan for the treatment of T2DM by improving insulin secretion; and hydroxychloroquine reduce the risk of coronary heart disease (CHD) by counteracting inflammation. Network medicine has the potential to improve precision medicine in diabetes care and enhance personalized therapy. However, only randomized clinical trials will confirm the clinical utility of network-oriented biomarkers and drugs in the management of DM.

Sign in / Sign up

Export Citation Format

Share Document